Carcinoembryonic cell adhesion molecule 6 (CEACAM6) is a glycosylated, GPI-anchored protein expressed in epithelial cells of various human tissues. It binds gram-negative bacteria and is overexpressed in cancers where it is anti-apoptotic and promotes metastases. To characterize CEACAM6 expression in developing lung, we cultured human fetal lung epithelial cells and examined responses to differentiation-promoting hormones, adenovirus expressing thyroid transcription factor (TTF-1), and silencing of TTF-1 using small inhibitory RNA. Glucocorticoid and cAMP had additive stimulatory effects on CEACAM6 content and combined treatment maximally increased transcription rate, mRNA, and protein ~10-fold. Knockdown of TTF-1 reduced hormone induction of CEACAM6 by 80%, and expression of recombinant TTF-1 increased CEACAM6 in a dose-dependent fashion. CEACAM6 content of lung tissue increased during the third trimester and postnatally. By immunostaining,
The IgCAM superfamily is a diverse group of adhesive receptor glycoproteins that contain an aminoterminal N domain, which is homologous to the Ig variable domain, and different numbers of domains homologous to the Ig constant domain. In the human, the carcinoembryonic antigen (CEA) gene family is an IgCAM subset consisting of 29 related genes and pseudogenes clustered at q13.2 on chromosome 19 (22) . CEA proteins function as intercellular homophilic and heterophilic adhesion molecules and have signaling properties. CEACAM6 (also called NCA, NCA-50/90 and CD66c) and CEACAM5 (originally called CEA and also designated CD66e) share ~90% homology of the N-domain but differ in the number of IgC2-like domains (A-and B-domains). Both proteins contain a glycophosphatidylinositol (GPI) membrane anchor (28) and are targeted to lipid rafts in apical membranes of polarized epithelial cells (32) . CEACAM5/6 bind a variety of gram-negative bacteria and mediate internalization/phagocytosis, participating in innate immune defense in the intestine (10) . The two genes are not found in rodents, and they may represent pathogen-host co-evolution, providing different protein structures with selective bacterial binding properties.
Expression of CEACAM5/6 is deregulated and over-expressed in cancers of colorectal epithelium, with surface levels inversely correlated with both the degree of colonocyte differentiation (26) and positive clinical outcome (27) . The two CEACAMs are also expressed in a high proportion of tumor cell lines derived from breast, ovary, pancreas, prostate and lung (8) . It has been proposed that CEACAM5/6 overproduction has a causative role in tumorigenesis, acting via an imbalance of cell surface adhesion molecules that disrupts differentiation, inhibits apoptosis and promotes both tumor formation and metastases (26, 39) .
Two earlier studies identified both CEACAM5 and CEACAM6 immunoreactivity in normal adult lung, with CEACAM5 localized to type II cells and CEACAM6 present in both alveolar and airway epithelium (43, 44) . At present, there is no published information regarding regulated expression or function of these proteins in the lung epithelium. In a recent study with human fetal lung we identified CEACAM6 as one of the genes up-regulated during hormone-induced differentiation of type II cells in vitro (46) . In addition, we found in preliminary experiments that CEACAM6 was also up-regulated in undifferentiated lung epithelial cells by expression of recombinant thyroid transcription factor (TTF-1, product of Nkx2.1), which is critical for differentiation of type II cells and expression of surfactantassociated proteins (31) . Mature type II cells produce pulmonary surfactant, a phospholipid-protein mixture that is essential for normal respiration by virtue of its ability to reduce surface tension and prevent collapse of airspaces. Type II cells also produce proteins that participate in innate defense against microorganisms and modulate fluid and ion flux between the alveolus and the epithelium, and they proliferate during fetal lung development and after lung injury to generate type I cells for gas exchange (16) .
Studies with human fetal lung explants and isolated epithelial cells have been useful in determining biochemical, morphological and functional changes in response to glucocorticoid plus cAMP treatment, which is carried out with serum-free, fully defined culture conditions using plastic substratum (2, 11, 19, 21) . Hormone-treated fetal epithelial cells differentiate to closely resemble mature adult type II cells with regard to synthesis of surfactant components, formation and regulated secretion of surfactant-containing lamellar bodies, and establishment of a cellular monolayer with high transepithelial resistance. Herein, we use cultured human lung cells to characterize hormonal and TTF-1 regulation of CEACAM6 expression, describe type II cell-specific synthesis and secretion, and provide evidence for functions of CEACAM6 in the lung alveolus. Lung cell isolation and culture and tracheal aspirates. Human fetal lung of 11-22 wk gestation abortuses was obtained from Advanced Bioscience Resources (Alameda, CA) and/or the Birth Defects Laboratory of the University of Washington (Seattle, WA); specimens of postnatal lung were obtained from postmortem tissue. Lung epithelial cells were isolated and cultured as previously described under approved IRB protocols of the Children's Hospital of Philadelphia (21) . Briefly, after overnight culture as explants (20) , the tissue was digested with trypsin, collagenase and DNase, and fibroblasts were removed by differential adherence. Nonadherent cells were plated on 60 mm plastic culture dishes in Waymouth's medium containing 10% fetal calf serum. After overnight culture (d 1), we cultured attached cells an additional 3-9 d in 1 ml of serum-free Waymouth's medium alone (control), or with dexamethasone (10 nM) plus 8-Br-cAMP (0.1 mM) and isobutylmethylxanthine (0.1 mM), a combination that is referred to as DCI, or with dexamethasone or 8-Br-cAMP/isobutylmethylxanthine separately.
MATERIALS AND METHODS

Materials
These concentrations maximally induce surfactant components in human lung explant cultures (20) .
Epithelial cell purity by this method is 86±2% by cytokeratin staining with fibroblasts as the primary contaminating cell type (19, 21) .
Type II cells were isolated from adult human lungs as described by Fang et al. (15) . Purity for 5 preparations was 94±1% by staining for SP-B and SP-C with fibroblasts as the major contaminating cell type.
Tracheal aspirate samples were collected from premature infants under an IRB-approved protocol.
Large aggregate surfactant was prepared by centrifugation at 27,000xg for 60 min.
Secretion studies. After 4 d culture in DCI, fetal lung cells received fresh medium and both media and cells were collected at subsequent time points. CEACAM6 content in cells and medium (concentrated by Amicon Centricon-10 filtration) was determined by Western analysis as described below. Percent secretion in each culture dish was calculated as density units in media divided by units in media + units in cells. A secretagogue mixture added to some cells contained TPA (10 nM) plus terbutaline (10 µM) plus Ca++ ionophore A23187 (100 nM). In some experiments cells were cultured in DCI for 24h with addition of mannosamine (10 mM) for the next 24-48 h at which time media and cells were harvested.
Recombinant adenovirus construction. The recombinant sense construct for TTF-1 (Ad12A2) was generated as described (31) using the Adeno-X Expression System as per the manufacturer's instructions (BD Biosciences, Clontech, Palo Alto, CA). The construct was generated under the CMV promoter in a replication-deficient adenovirus H5.010 to facilitate high expression levels and was subcloned into a pShuttle plasmid to generate an expression cassette. Purified adenovirus was used to infect fetal lung epithelial cells. Control adenovirus (AdGFP) was constructed containing pEGFP coding sequence under a CMV promoter and was used in initial experiments to determine infection efficiency at various viral titers. For transduction studies, cells were exposed to either AdGFP or Ad12A2 at titers of 0.2 to 7 pfu/cell and residual virus was removed by medium change after 24 h.
siRNA silencing of TTF-1 and CEACAM6. Silencing small inhibitory RNA oligonucleotides (siRNA) for TTF-1 and CEACAM6 were synthesized and purified by Qiagen-Xeragon (Germantown, MD).
Oligonucleotides A and D for TTF-1 each reduced TTF-1 protein in fetal lung cells by ≥50% (31). For CEACAM6, sequences are as follows: forward: r(5'-GUC CUG CUC ACA GCC UCA CUU CUA A); reverse: r(5'-UUA GAA GUG AGG CUG UGA GCA GGA C). Inhibition in the presence of siRNA was ≥90 %. Scrambled (control) oligonucleotides had no homology with relevant human genes by BLAST analysis; the sequences were: forward: r(5'-GUC CUC GGA CAC UCC UUC ACU CUA A); reverse: r(5'-UUA GAG UGA AGG AGU GUC CGA GGA C). Cells were treated with siRNA oligonucleotides (200 nM) by nucleofection according to the manufacturer's protocol using epithelial cell specific buffer (AMAXA Inc., Gaithersburg, MD). Cell viability after electroporation was ~50%.
Real-time RT-PCR. Total RNA was prepared from lung cells using RNA STAT-60 (Tel-Test, Inc., Friendswood, TX) and treated with RQ1 RNase-free DNase. Integrity and purity were determined with Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, CA). Real-Time PCR reactions were performed in the Real-Time PCR Facility of the Stokes Research Institute at Children's Hospital of Philadelphia as previously described (31) . Specific primers and probe sequences are available on request.
Transcription rate. Nuclei were isolated from cultured cells and nuclear run-on reactions were performed by a slight modification of the method of Hildebrandt and Neufer (24) . The nascent RNA transcripts were extracted using RNA Stat-60 (Tel-Test Inc, Friendswood, TX) and Real-Time PCR was performed (in triplicates) as described above. CEACAM6 transcription rate data were expressed relative to the transcription rate of GAPDH.
Whole cell extract preparation. Whole cell extracts were prepared from fetal lung cells by standard procedures. In brief, cells were washed once with PBS and lysed by sonication in ice-cold buffer containing 50 mM Tris HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 1 mM EDTA, 2 mM dithiothreitol (DTT), 1 mM phenylmethylsulphonylfluoride (PMSF), 5 μg/ml leupeptin, 5 ug/ml apoprotein and 5 ug/ml antipain. The lysates were centrifuged at 10,000xg for 10 min at 4 0 C and supernatants were used for Western analysis. Protein concentrations were determined by Bio-Rad protein assay reagent kit using a microplate assay protocol (Bio-Rad Laboratories, Hercules, CA).
Western analysis. Western blot analyses for TTF-1, SP-B, CEACAM6, ß-actin and GAPDH were performed as described previously (21 (7).
RESULTS
CEACAM6 is developmentally regulated and transcriptionally induced by glucocorticoid and cAMP
Using microarray analysis, we determined the expression and hormonal responsiveness of CEACAM family members in fetal lung cells (Table) . In control fetal epithelial cells, cultured 3 days in the absence of serum and hormones, mRNAs for CEACAMs 1, 4, 5 and 6 were present at significantly detectable levels whereas there was no significant signal for CEACAMs 3, 7 and 8. Expression of CEACAMs 1 and 4 was not affected by exposure to DCI, CEACAM5 was modestly induced (2-fold), and CEACAM6 was induced 10-fold. In type II cells from adult lung, CEACAMs 1, 5 and 6 were expressed at higher levels than for fetal cells. These findings indicate that CEACAM6 is the most highly expressed and regulated member of the CEACAM family of genes in fetal lung epithelial cells and suggest developmental regulation.
We further examined the developmental pattern for CEACAM6 by Western analysis of lung tissue.
As shown in Figure 1A , protein content was low to undetectable between 13 and 27 weeks of fetal life and expression was progressively increased in third trimester and postnatal specimens. This pattern is consistent with developmental expression in parallel with Type II cell differentiation.
To characterize the induction process, we first examined the response of CEACAM6 to individual hormone treatments. On Western analysis of cell sonicates, the major CEACAM6 immunoreactive band was detected at ~ 90 kDa with a minor band at ~70 kDa ( Figure 1B ). CEACAM6 protein content increased ~5-fold with 4 d exposure to combined hormone treatment (DCI), with lesser and additive responses to each agent alone ( Figure 1C ).
Increased CEACAM6 mRNA content could reflect higher transcription rate and/or changes in transcript stability. To address the former mechanism, we performed nuclear run-on experiments for CEACAM6 gene transcription. After a lag of 2-4 h, the transcription rate increased in a linear fashion on DCI exposure and was 10.6±4.1-fold greater than control at 48 h ( Figure 1D ). Increased transcription preceded the increase in both cellular CEACAM6 mRNA content, which was not significantly increased until 12-16 h (data not shown), and CEACAM6 protein ( Figure 1E and 1F). In the same experiments the transcription rate for SP-B, which is synergistically induced by glucocorticoid plus cAMP (19) , was maximal by ~12 h (data not shown). The delayed time course of increased CEACAM6 transcription rate suggests that induction might be a secondary rather than a primary response to hormones.
Because of the low level of CEACAM6 expression in untreated cells, it was not possible to directly compare mRNA stability with and without hormone treatment. Instead, we determined content of CEACAM6 mRNA, by real time PCR, with time after removal of DCI from treated cells, anticipating a slower decay rate initially if hormones were stabilizing transcript. In three experiments there was a log-linear decay of CEACAM6 mRNA with a calculated half-life of 15.3 ± 4.0 h and r ≥0.94. This finding is consistent with a primary effect of hormones on CEACAM6 transcription rate.
CEACAM6 is a TTF-1 target gene
We previously observed that expression of CEACAM6 mRNA and protein in control lung cells was increased by exposure to adenovirus (Ad12A2) expressing recombinant TTF-1 (rTTF-1), a key, inducible transcription factor in type II cell differentiation (31) . Additional experiments were performed to further characterize the role of TTF-1 in CEACAM6 expression. As shown in Figure Collectively, the findings with rTTF-1 and silencing establish a role for TTF-1 in regulating expression of CEACAM6.
TTF-1 regulation of CEACAM6 expression could represent either a direct response, mediated via binding to promoter elements, or an indirect effect that requires other TTF-1-or DCI-inducible factors.
We therefore examined the requirement for continuing protein synthesis in DCI induction of CEACAM6. 
CEACAM6 is induced in type II but not mesenchymal cells
The fetal lung cell cultures used in this study contain ~14% non-epithelial cells, which are primarily fibroblasts (21) . Accordingly, we investigated expression of CEACAM6 by lung cell type. Fibroblasts were isolated at >95% purity from lung tissue in parallel with epithelial cell isolation. By Western analysis ( Figure 5A ), CEACAM6 was barely detectable in control cultures of both epithelial cells (row 2, lanes 1 and 3) and lung fibroblasts (row 2, lanes 5 and 7). After exposure to DCI, strong CEACAM6 staining was observed for epithelial cells (row 2, lanes 2 and 4) but not for fibroblasts (row 2, lanes 6 and We used confocal microscopy to localize expression of CEACAM6 within fetal type II cells. As shown in Figure 5D (left panel), CEACAM6 was observed as punctate perinuclear immunostaining and also at the cell periphery (e.g., arrow). As illustrated in the middle panel, and at higher magnification in the right panel, most of the punctate CEACAM6 staining colocalized with that for SP-B, a marker for lamellar bodies (47) . This colocalization staining pattern is different from that observed for DC-LAMP, which is localized to the lamellar body periphery (limiting membrane), and is distinct from SP-B staining (46) . This finding indicates the presence of CEACAM6 within surfactant-containing organelles of type II cells.
CEACAM6 is secreted from fetal type II cells
Elevated levels of CEACAM6 are found in plasma of many patients with lung cancer (3, 33) , however secretion of the protein into lung airspaces has not been examined. We determined the secretion rate of In the secretion experiments, the large aggregate surfactant fraction from pooled media contained ~2.1% of the total media CEACAM6, which is 30-fold more than the expected contribution from media contamination of the pelleted surfactant, and CEACAM6 was ~0.3% of the total protein (n=2). Thus a fraction of CEACAM6 in conditioned medium is lipid-associated, which could occur either prior to lamellar body release or post-release. In preliminary experiments we found no increase in CEACAM6
release from cultured cells in the presence of secretagogues (TPA + terbutaline + calcium ionophore A23187).
To explore the role of glycosylation and the GPI anchor of CEACAM6 in secretion, cells were treated with mannosamine, which competes for mannose and blocks glycosylation and GPI anchor formation To examine secretion in vivo, we assessed CEACAM6 in tracheal aspirates from intubated premature infants. Tracheal aspiration uses saline instillation and suctioning and collects epithelial lining fluid from upper airways; tracheal aspirate fluid has been used to obtain surfactant for analysis (7) . As shown in the representative Western of Figure 6D , we found both CEACAM5 and CEACAM6 (upper and lower bands, respectively, of lanes 1-6) in 3 aspirate samples from an infant at 10-41 d after birth; the migration patterns and ratio of CEACAM5 to CEACAM6 signal were comparable to those observed for cultured fetal lung cells (lanes 8 and 9). CEACAM5 and 6 was present in both the large aggregate surfactant pellet (lanes 1-3) and the supernatant fraction (lanes 4-6) of each tracheal aspirate. In analysis of 40 tracheal aspirate samples, 41±4% (mean/SE) of total aspirate CEACAM6 was associated with the surfactant pellet. These findings indicate that CEACAM6 is present in airways of human infants with lung disease, presumably secreted in part from alveolar type II cells and associated with pulmonary surfactant.
CEACAM6 is a multi-functional lung protein
The ability of CEACAM6 to bind selected bacteria, including human-specific respiratory microorganisms, has been well characterized both in vitro and in studies with non-pulmonary epithelial primary cells and cell lines (10, 25, 45 (29) . To test this possibility, we first performed experiments to examine apoptotic markers in DCI-treated cells with and without siRNA silencing of CEACAM6 expression (as illustrated in Figure 3 ). As shown in the representative immunofluorescence images of Figure 7A Second, we measured caspase-3 activity in cells with/without silencing of CEACAM6 expression. As shown in Figure 7C , caspase activity was increased 2.5-fold in type II cells treated with siRNA compared to cells receiving control RNA (si-ct) or no RNA (electroporated control and DCI-treated cells). The results from both staining and caspase assay indicate that expression of CEACAM6 inhibits apoptosis of cultured fetal type II cells in the face of electroportion as an apoptotic stimulus (40) . Of interest, caspase-3 activity was relatively low in electroporated control cells, which contain low levels of CEACAM6. We propose that hormone-induced differentiation of fetal epithelial cells induces a pro-apoptotic change in the cells that is repressed by increased levels of CEACAM6. Previous microarray data indicated that expression of a number of pro-and anti-apoptotic genes changed after exposure to DCI (46) .
Because of our finding that CEACAM6 was associated with surfactant both intracellularly (lamellar bodies, Figure 5D ) and in epithelial lining fluid in vivo ( Figure 6D ), we investigated potential effects of CEACAM6 on surfactant function. In initial studies we tested for effects of CEACAM6 on surface active properties of surfactant in the presence of inhibitory exogenous proteins. A commercial natural surfactant (Infasurf) was incubated with conditioned medium from fetal type II cells treated with either CEACAM6 siRNA or scrambled oligonucleotide (control). Conditioned medium from CEACAM6-silenced cells ( Figure 7D si oligo, upper line) was inhibitory for development of a low minimum surface tension in a pulsating bubble surfactometer; the minimum surface tension achieved was ~15 mN/m compared to ~zero for surfactant incubated with fresh culture medium (Infasurf, lowest line). By contrast, medium without knockdown of CEACAM6 (control oligo, middle line) was much less inhibitory, achieving a minimum surface tension <2 mN/m after 4 min pulsation.
DISCUSSION
In this study we report the first characterization of CEACAM6 in human lung epithelial cells and provide evidence for unique regulation and lung-specific functions. We initially identified CEACAM6 as a protein of interest based on up-regulation of its gene expression during hormone-induced fetal type II cell differentiation. In our model of differentiation, using microarray analysis, a subset of genes (7.1% of expressed genes) are induced >1.5-fold by hormone treatment; CEACAM6 was notable for a relatively high level of induction (~10-fold) (46) . In this culture system, undifferentiated epithelial cells of fetal lung develop morphological and biochemical characteristics of mature type II cells after exposure to glucocorticoid and cAMP, agents that modulate fetal lung maturation in vivo (21) . Functional differentiation responses include synthesis of various surfactant components, secretion of active surfactant, and formation of a tight epithelial monolayer with regulated ion and fluid transport.
Accordingly, the in vitro culture model represents precocious type II cell differentiation mimicking the process that occurs in vivo during the third trimester of human gestation. It is likely, therefore, that the properties of CEACAM6 regulation and function that we describe also occur in vivo.
Maximal expression of CEACAM6 in fetal lung cells required the presence of both dexamethasone and cAMP agents, with a response pattern similar to that for induction of TTF-1 (21) . In this regard, hormonal regulation of CEACAM6 resembles that for many of the up-regulated genes during in vitro type II cell differentiation (21) . In addition, for those studied, hormonally induced genes of fetal lung are developmentally regulated and expressed in mature, adult type II cells as we found for CEACAM6 (4).
Both glucocorticoids and cAMP are known to promote tissue differentiation; in vivo, lung corticoid content increases with development and PGE2 is a possible stimulus for increased cAMP in fetal lung cells (1, 5, 6) .
When hormones were added 72h after cell isolation, the time course for CEACAM6 induction was relatively slow with a considerable lag time. Delayed induction suggests that CEACAM6 is a product of differentiation rather than a signaling molecule involved in the differentiation process. In vivo, the content of CEACAM6 on colonic epithelial cells increases as the cells migrate and differentiate (22), however the mechanism of induction in colonocytes has not been examined. For CEACAM6 of fetal lung cells, hormone treatment increased the rate of transcription comparable to the level of increased mRNA. Similarly, transcriptional regulation, rather than enhanced transcript stability, occurs for most other target genes in fetal lung cells that have been examined (4).
Using both gain and loss of function approaches we have established that CEACAM6 is a target gene for TTF-1. This transcription factor, which is encoded by TITF1 (formerly Nkx2.1), is a homeodomaincontaining phosphoprotein that is expressed in thyroid, lung and areas of the brain. TTF-1 is required for normal structural development of the mouse lung (30) and regulates expression of a limited number of genes in developing type II cells (31) (9, 50) . Factors that repress TTF-1 would be expected to decrease TTF-1 target genes such as CEACAM6, and we have found that this response occurs for TGF-β (36). Regulation of CEACAM6 by TTF-1 has possible implications for the origin and metastatic potential of lung adenocarcinomas. A proportion of these tumors apparently arise from type II cells and continue to express TTF-1, in some cases at elevated levels. Moreover, both TTF-1 and CEACAM6 are marker genes that are specific for lung adenocarcinomas versus other types of lung cancers, and both proteins are highly expressed in some lung adenocarcinoma cell lines (8) . We propose that transformation of type II cells in some lung adenocarcinomas involves mutagenic insults resulting in increased TTF-1 content, elevated and dysregulated expression of CEACAM6, and subsequent alterations in cell proliferation and adhesion properties. Accordingly, TTF-1 and CEACAM6 may be potential therapeutic targets for selected lung adenocarcinomas.
TTF-1 is decreased in type II
In addition to CEACAM6, fetal type II cells expressed CEACAMs 1, 4 and 5 at relatively low levels, and adult cells also express 1 and 5. CEACAM5 was the only other family member in fetal cells that was responsive to hormones. This pattern of CEACAM expression is similar to that in human colonocytes.
Moreover, expression of both CEACAM5 and CEACAM6 is up-regulated in vivo during colonocyte differentiation (26, 43 ). We did not study regulation of CEACAM5, which is modestly induced in fetal lung cells. CEACAM5 and CEACAM6, along with other members of the CEA subgroup, are clustered at q13.2 on chromosome 19, and the proximal promoters of the two genes are highly homologous (23) . It is possible that these two CEACAMs display similar responses to hormone exposure and developmental signals and have overlapping functions in the lung.
In confocal immunofluorescence studies we found that CEACAM6 localized to intracellular vesicles as well as the plasma membrane of fetal type II cells. Colocalization with SP-B indicated that CEACAM6 was present within lamellar bodies rather than in the limiting membrane such as occurs for alkaline phosphatase, LAMP3 (DC-LAMP, lysosomal associated membrane protein), and ABCA3 (ATP binding cassette A3), which has a putative phospholipid transport function (37, 38, 46) . Other identified proteins within lamellar bodies include SP-A, SP-C and pepsinogen C (Guttentag, S, unpublished observation), which are all related to pulmonary surfactant function or synthesis (18) . The function of CEACAM6 in lamellar bodies is not known, however we speculate that it is targeted to developing lamellar bodies and interacts with the phospholipid bilayers via its GPI anchor.
CEACAM6 that is released from fetal type II cells into the media may represent both secretion of lamellar bodies and shedding of protein from the plasma membrane. We did not observe a significant increase in CEACAM6 release in the presence of secretagogues, which is likely due to the high level of release in the absence of secretagogues (i.e., a masking effect). In vivo, CEACAM6 is presumably secreted with surfactant during lamellar body exocytosis and a portion remains surfactant-associated in the alveolus. Approximately half of CEACAM6 in epithelial lining fluid of infant tracheal aspirates was found in the large aggregate surfactant fraction, and half was present in the supernatant fraction, which contains small aggregate (recycling) surfactant and non-surfactant components. Supernatant CEACAM6 could represent in part protein released from the plasma membrane, which presumably lacks the GPI anchor and has a lower affinity for surfactant. Secretion was reduced in cells exposed to mannosamine, which inhibits glycosylation and GPI formation. Alternatively, the presence of CEACAM6 in both surfactant and supernatant fractions may reflect a moderate binding affinity of CEACAM6 for surfactant phospholipid and thus equilibrium distribution. Ongoing studies are addressing this question as well as content of secreted CEACAM6 related to the clinical status of infants.
We found that CEACAM6 content of fetal lung cells was a strong determinate of apoptosis. Overexpression of CEACAM5/CEACAM6 in transformed cell lines inhibits apoptosis of cells that are detached from their basement membrane (26, 39) , however, to our knowledge, this is the first observation for a role of endogenous CEACAM6 in programmed death of normal, non-transformed cells. The stimulus for apoptosis in our studies is apparently electroporation and/or presence of transfected RNA.
The physiological role for CEACAM6 in type II cell proliferation/apoptosis is uncertain; future studies will identify targets of CEACAM6 related to apoptosis.
To date, four different proteins have been assigned the name "pulmonary surfactant protein". SP-B
and SP-C are highly hydrophobic proteins that are packaged within lamellar bodies and remain surfactantassociated in the alveolus where they participate in formation and stability of the surfactant surface film (48) . SP-A is primarily secreted by a constitutive mechanism, independent of surfactant, In summary, we found that CEACAM6 in fetal lung epithelium is developmentally and hormonally regulated and that expression is specific for type II alveolar cells. Increased content of TTF-1 is sufficient to induce CEACAM6, but this response appears to be indirect and to involve other induced factor(s).
CEACAM6 is localized to both the plasma membrane and lamellar bodies of cells and is found in surfactant isolated from airways, suggesting that CEACAM6 is a newly identified member of the 
FIGURE LEGENDS
Figure. RNA was analyzed by microarray using Affymetrix U133A chips (46) . Four of seven CEACAM family members (1, 4, 5, 6) were expressed in both control and DCI-treated fetal cells (cultured 72 h), but only CEACAMs 5 and 6 were induced by DCI (2-fold and 10-fold, respectively, n=5, p<0.003). Freshly isolated adult cells from 5 experiments expressed CEACAMs 1, 5 and 6 at higher levels than for fetalcells. Intensity data are fluorimetric units (f.u., mean±SE).
